Cargando…

Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice

OBJECTIVE: To examine the impact of initiating treatment with eslicarbazepine acetate (ESL) on healthcare resource utilization (HCRU) among pediatric patients with focal seizures (FS). METHODS: This retrospective study used Symphony Health’s Integrated Dataverse(®) claims data. Patients aged 4 to 17...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Darshan, Davis, Matthew, Epstein, Andrew J, Williams, G Rhys
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384864/ https://www.ncbi.nlm.nih.gov/pubmed/32801808 http://dx.doi.org/10.2147/CEOR.S261960

Ejemplares similares

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
por: Mehta, Darshan, et al.
Publicado: (2020)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
por: Mehta, Darshan, et al.
Publicado: (2021)

Healthcare Resource Utilization Among Patients with Focal Seizures Treated with Eslicarbazepine Acetate in the US Long-Term Care Setting: A Retrospective Claims Database Analysis
por: Mehta, Darshan, et al.
Publicado: (2021)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018)

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
por: Mintz, Mark, et al.
Publicado: (2019)

Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy
por: Pellegrino, Giovanni, et al.
Publicado: (2018)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
por: Soares-da-Silva, Patrício, et al.
Publicado: (2015)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
por: Fei, Yanqing, et al.
Publicado: (2022)

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience
por: Gama, Helena, et al.
Publicado: (2017)

Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
por: Galiana, Graciana L., et al.
Publicado: (2017)

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures
por: Sunkaraneni, Soujanya, et al.
Publicado: (2018)

Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
por: Magalhães, Luís M., et al.
Publicado: (2021)

Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
por: Winter, Yaroslav, et al.
Publicado: (2022)

Clinical utility of eslicarbazepine: current evidence
por: Zaccara, Gaetano, et al.
Publicado: (2015)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study
por: Chaves, J., et al.
Publicado: (2017)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
por: Lawthom, Charlotte, et al.
Publicado: (2018)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
por: Tambucci, Renato, et al.
Publicado: (2016)

A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy
por: Hirsch, Martin, et al.
Publicado: (2023)

Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus
por: Sierra-Paredes, Germán, et al.
Publicado: (2014)

Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures
por: Villanueva, Vicente, et al.
Publicado: (2017)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies
por: Elger, Christian, et al.
Publicado: (2017)

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension study
por: Trinka, Eugen, et al.
Publicado: (2023)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
por: Singh, Rajinder P., et al.
Publicado: (2011)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017)

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
por: Brown, Martin E, et al.
Publicado: (2010)

Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials
por: Carreño, Mar, et al.
Publicado: (2017)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
por: Jacobson, Mercedes P, et al.
Publicado: (2015)

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies
por: Shorvon, S. D., et al.
Publicado: (2017)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na(v)1.5 Channels
por: Leslie, Theresa K., et al.
Publicado: (2020)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies
por: Sperling, Michael R., et al.
Publicado: (2016)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
por: Iram, Farah, et al.
Publicado: (2018)

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli
por: Sales, Francisco, et al.
Publicado: (2020)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
por: Hwang, Sejung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prf9dinkr79172m7a584mgt56o